Released September 15, 2020 | NEW DELHI
en
India's Central Drugs Standard Control Organisation (CDSCO) recently granted approval to pharmaceutical majors Cipla Limited and Optimus Pharma Limited to conduct Phase IV trials for Favipiravir, the most sought-after medicine in the treatment of mild to moderate symptoms of COVID-19.
The CDSCO's Subject Expert Committee gave its nod after the two Favipiravir-manufacturing firms submitted their proposals. The Subject Expert Committee advises India's apex regulator, Drug Controller General of India (DCGI), on applications seeking approvals for new drugs, vaccines and clinical trials.
Favipiravir is a generic version of Avigan, a drug manufactured by Fujifilm Toyama Chemical, a subsidiary of Japan's Fujifilm Corporation. India approved its use as an anti-flu drug in 2014. Following the outbreak of COVID-19, pharmaceutical manufacturers across India have initiated multiple clinical trials of Favipiravir.
Industrial Info is tracking 67 active COVID-19 related projects in India, worth more than $387 million. Click here for a list, and see heat map below from Industrial Info's Geolocator tool.
The CDSCO's Subject Expert Committee gave its nod after the two Favipiravir-manufacturing firms submitted their proposals. The Subject Expert Committee advises India's apex regulator, Drug Controller General of India (DCGI), on applications seeking approvals for new drugs, vaccines and clinical trials.
Favipiravir is a generic version of Avigan, a drug manufactured by Fujifilm Toyama Chemical, a subsidiary of Japan's Fujifilm Corporation. India approved its use as an anti-flu drug in 2014. Following the outbreak of COVID-19, pharmaceutical manufacturers across India have initiated multiple clinical trials of Favipiravir.
Industrial Info is tracking 67 active COVID-19 related projects in India, worth more than $387 million. Click here for a list, and see heat map below from Industrial Info's Geolocator tool.
